Zacks Research Comments on ACADIA Pharmaceuticals Inc.’s FY2025 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Zacks Research cut their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $0.93 per share for the year, down from their previous forecast of $0.94. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.62 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q1 2026 earnings at $0.41 EPS and FY2026 earnings at $1.28 EPS.

ACAD has been the topic of several other research reports. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 30th. Oppenheimer reiterated a “market perform” rating and issued a $25.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, February 5th. Morgan Stanley decreased their price objective on shares of ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 9th. Finally, JMP Securities reissued a “market outperform” rating and set a $42.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $35.82.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $16.99 on Tuesday. The stock’s fifty day moving average is $20.64 and its 200 day moving average is $23.72. ACADIA Pharmaceuticals has a one year low of $16.60 and a one year high of $33.99. The stock has a market cap of $2.80 billion, a P/E ratio of -44.71 and a beta of 0.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The business had revenue of $231.04 million during the quarter, compared to the consensus estimate of $223.79 million. During the same quarter in the previous year, the business posted ($0.26) earnings per share. The firm’s revenue was up 69.3% on a year-over-year basis.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Quest Partners LLC bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $39,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $100,000. China Universal Asset Management Co. Ltd. grew its stake in shares of ACADIA Pharmaceuticals by 97.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,202 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 2,070 shares during the last quarter. Legato Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth approximately $206,000. Finally, Old Well Partners LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth approximately $257,000. 96.71% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Stephen Davis sold 26,574 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $474,877.38. Following the completion of the transaction, the chief executive officer now directly owns 144,267 shares of the company’s stock, valued at $2,578,051.29. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Stephen Davis sold 26,574 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $474,877.38. Following the completion of the transaction, the chief executive officer now owns 144,267 shares of the company’s stock, valued at approximately $2,578,051.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Brendan Teehan sold 2,568 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $17.87, for a total value of $45,890.16. Following the sale, the chief operating officer now directly owns 38,796 shares in the company, valued at $693,284.52. The disclosure for this sale can be found here. Insiders have sold a total of 69,383 shares of company stock valued at $1,291,362 in the last quarter. 27.50% of the stock is currently owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.